P1/2, N=66, Not yet recruiting, Zhejiang Teruisi Pharmaceutical Inc.

P1, N=147, Active, not recruiting, Zhejiang Teruisi Pharmaceutical Inc. | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Jul 2025

P2, N=139, Not yet recruiting, Zhejiang Teruisi Pharmaceutical Inc.

P1, N=152, Recruiting, Zhejiang Teruisi Pharmaceutical Inc. | Trial completion date: Nov 2022 --> Dec 2024 | Trial primary completion date: Aug 2022 --> Dec 2023

P1, N=18, Suspended, Mayo Clinic | Trial completion date: Jun 2023 --> Apr 2024 | Recruiting --> Suspended

P1, N=121, Recruiting, Zhejiang Teruisi Pharmaceutical Inc.

In this small study, there was a statistical increase in CD4, CD14, CD68, CD8A, B7-H3, PDL-1, CD19, FOXP3, CD44, and STAT3 protein expression in methylated versus unmethylated GBM tumour core; however, this requires larger cohort validation. Advanced multiplex immunooncological biomarker analysis may be useful in identifying biomarkers for novel immunotherapeutic agents in GBMs.

B7-H3 is an important target for immuno-oncology agents for childhood cancers . Our results provide proof-of-principle for the ability of MGC018 to produce profound antitumor activity in select pediatric solid tumor models in a B7-H3 specific manner.

The incorporation of CD20 monoclonal antibodies (e.g. rituximab) has improved cure rates from 35% to 50% in those with precursor B-cell ALL and from 40 to 80% in those with Burkitt leukemia. More novel antibodies, such as drug conjugates antibodies (e.g. inotuzumab ozogamicin) and bispecific T-cell engagers (e.g. blinatumomab), have shown significant promise in improving outcomes in the relapsed and refractory setting and are currently being studied in the frontline setting, with hopes to further improve long-term outcomes. In this chapter, we will review the role of monoclonal antibodies and how the incorporation of these agents has revolutionized and changed the treatment management of ALL in the frontline setting.

Targeting CD20 with the monoclonal antibody rituximab has improved survival in patients with aggressive B-cell lymphomas, the majority of which are cured with chemoimmunotherapy...The approval of the antibody drug conjugate polatuzumab in combination with chemoimmunotherapy has offered survival benefit to patients who are not candidates for more aggressive approaches and has the potential to change the standard of care for initial management...Herein, promising targets in aggressive lymphoma with the greatest potential for improving outcomes in these patients are discussed. Novel therapies, their toxicities, and their potential role in initial or subsequent treatment are highlighted.